These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 34599933)

  • 21. BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients.
    Yau K; Tam P; Chan CT; Hu Q; Qi F; Abe KT; Kurtesi A; Jiang Y; Estrada-Codecido J; Brown T; Liu L; Siwakoti A; Leis JA; Levin A; Oliver MJ; Colwill K; Gingras AC; Hladunewich MA
    Clin J Am Soc Nephrol; 2024 Jan; 19(1):85-97. PubMed ID: 37847518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection.
    Motwani KK; Hashash JG; Farraye FA; Kappelman MD; Weaver KN; Zhang X; Long MD; Cross RK
    J Crohns Colitis; 2023 Nov; 17(10):1681-1688. PubMed ID: 37232444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries.
    Dag Berild J; Bergstad Larsen V; Myrup Thiesson E; Lehtonen T; Grøsland M; Helgeland J; Wolhlfahrt J; Vinsløv Hansen J; Palmu AA; Hviid A
    JAMA Netw Open; 2022 Jun; 5(6):e2217375. PubMed ID: 35699955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.
    Syversen SW; Jyssum I; Tveter AT; Tran TT; Sexton J; Provan SA; Mjaaland S; Warren DJ; Kvien TK; Grødeland G; Nissen-Meyer LSH; Ricanek P; Chopra A; Andersson AM; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Lund-Johansen F; Jørgensen KK; Goll GL
    Arthritis Rheumatol; 2022 Aug; 74(8):1321-1332. PubMed ID: 35507355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.
    Ferretti F; Cannatelli R; Benucci M; Carmagnola S; Clementi E; Danelli P; Dilillo D; Fiorina P; Galli M; Gallieni M; Genovese G; Giorgi V; Invernizzi A; Maconi G; Maier JA; Marzano AV; Morpurgo PS; Nebuloni M; Radovanovic D; Riva A; Rizzardini G; Sabiu G; Santus P; Staurenghi G; Zuccotti G; Sarzi-Puttini PC; Ardizzone S
    Front Immunol; 2021; 12():656362. PubMed ID: 33936084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
    Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
    Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination.
    Firinu D; Perra A; Campagna M; Littera R; Fenu G; Meloni F; Cipri S; Sedda F; Conti M; Miglianti M; Costanzo G; Secci M; Usai G; Carta MG; Cappai R; Orrù G; Del Giacco S; Coghe F; Chessa L
    Clin Exp Med; 2022 Aug; 22(3):477-485. PubMed ID: 34741188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection by Type and Frequency of Vaccine: A Community-Based Case-Control Study.
    Gim H; Seo H; Chun BC
    J Korean Med Sci; 2024 Jun; 39(21):e174. PubMed ID: 38832478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.
    Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA
    Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.
    Caldera F; Rolak S; Farraye FA; Necela BM; Cogen D; Zona EE; Schell TL; Ramirez OR; Almasry M; Chun K; Hayney MS; Knutson KL
    Clin Transl Gastroenterol; 2024 Apr; 15(4):e00688. PubMed ID: 38349178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
    Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
    Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study.
    Bowdish DME; Chandran V; Hitchon CA; Kaplan GG; Avina-Zubieta JA; Fortin PR; Larché MJ; Boire G; Gingras AC; Dayam RM; Colmegna I; Lukusa L; Lee JLF; Richards DP; Pereira D; Watts TH; Silverberg MS; Bernstein CN; Lacaille D; Benoit J; Kim J; Lalonde N; Gunderson J; Allard-Chamard H; Roux S; Quan J; Hracs L; Turnbull E; Valerio V; Bernatsky S;
    J Rheumatol; 2024 Jul; 51(7):721-727. PubMed ID: 38621797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Response to COVID-19 Vaccination in Elite Athletes.
    Halmans L; Venhorst A; Klemis V; Schmidt T; Greiß F; Sester U; Gärtner BC; Sester M; Meyer T
    Exerc Immunol Rev; 2024; 30():63-70. PubMed ID: 39094182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study.
    Hitchon CA; Mesa C; Bernstein CN; Marrie RA; Card C; O'Brien SF; Kim J
    BMJ Open; 2023 May; 13(5):e071397. PubMed ID: 37253487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
    Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment of human post-vaccination SARS-CoV-2 standard reference sera.
    Xiang J; Katz L; Winokur PL; Chaudhary A; Digmann B; Bradford R; Rashid S; Ghosh S; Robertson A; Menetski J; Xu M; Gao P; Chen CZ; Lee T; Poelaert B; Eastman RT; Hall MD; Stapleton JT
    J Immunol Methods; 2024 Jul; 530():113698. PubMed ID: 38823574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
    Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
    BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.